Trial Outcomes & Findings for A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT NCT03038100)

Last Updated: 2023-02-17

Results Overview

Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1301 participants

Primary outcome timeframe

From randomization until disease progression or death from any cause (up to approximately 55 months)

Results posted on

2023-02-17

Participant Flow

The study is considered "Completed" because all pre-planned study activities and analyses have been performed.

Participant milestones

Participant milestones
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Study STARTED	650	651
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	650	651

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Study Death	289	272
Overall Study Lost to Follow-up	9	10
Overall Study Protocol Deviation	1	4
Overall Study Withdrawal by Subject	45	51
Overall Study Study Terminated By Sponsor	305	311
Overall Study Physician Decision	1	3

Baseline Characteristics

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=650 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=651 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.	Total n=1301 Participants Total of all reporting groups
Age, Continuous	59.3 Years STANDARD_DEVIATION 10.7 • n=5 Participants	58.9 Years STANDARD_DEVIATION 10.5 • n=7 Participants	59.1 Years STANDARD_DEVIATION 10.6 • n=5 Participants
Sex: Female, Male Female	650 Participants n=5 Participants	651 Participants n=7 Participants	1301 Participants n=5 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	38 Participants n=5 Participants	39 Participants n=7 Participants	77 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	598 Participants n=5 Participants	589 Participants n=7 Participants	1187 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	14 Participants n=5 Participants	23 Participants n=7 Participants	37 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	6 Participants n=5 Participants	5 Participants n=7 Participants	11 Participants n=5 Participants
Race (NIH/OMB) Asian	155 Participants n=5 Participants	150 Participants n=7 Participants	305 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants
Race (NIH/OMB) Black or African American	13 Participants n=5 Participants	8 Participants n=7 Participants	21 Participants n=5 Participants
Race (NIH/OMB) White	461 Participants n=5 Participants	464 Participants n=7 Participants	925 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	15 Participants n=5 Participants	22 Participants n=7 Participants	37 Participants n=5 Participants

PRIMARY outcome

Timeframe: From randomization until disease progression or death from any cause (up to approximately 55 months)

Population: Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=650 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=651 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population	18.37 Months Interval 17.22 to 19.75	19.48 Months Interval 18.14 to 20.76

PRIMARY outcome

Timeframe: From randomization until disease progression or death from any cause (up to approximately 55 months)

Population: PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=393 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=391 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation	18.50 Months Interval 16.62 to 21.36	20.83 Months Interval 19.06 to 24.21

PRIMARY outcome

Timeframe: From randomization up to death from any cause (up to approximately 59 months)

Population: Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.

Overall Survival (OS) is defined as the time from randomization to death from any cause.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=650 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=651 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Survival - ITT Population	46.59 Months Interval 45.31 to 49.74	50.53 Months Interval 46.26 to The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.

PRIMARY outcome

Timeframe: From randomization up to death from any cause (up to approximately 59 months)

Population: PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.

Overall Survival (OS) is defined as the time from randomization to death from any cause.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=393 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=391 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Survival - PD-L1-Positive Subpopulation	49.15 Months Interval 45.54 to The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months 67.3% of the participants were censored and the median was not reached.

SECONDARY outcome

Timeframe: From randomization until disease progression or death from any cause (up to approximately 55 months)

Population: Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the ITT population with measurable disease at baseline.

OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=650 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=651 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population	88.7 Percentage of participants	92.8 Percentage of participants

SECONDARY outcome

Timeframe: From randomization until disease progression or death from any cause (up to approximately 55 months)

Population: Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the PD-L1-Positive subpopulation with measurable disease at baseline.

OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=393 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=391 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population	89.9 Percentage of participants	92.3 Percentage of participants

SECONDARY outcome

Timeframe: From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)

Population: Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.

DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=650 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=651 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population	14.06 Months Interval 13.01 to 16.62	16.59 Months Interval 14.52 to 19.09

SECONDARY outcome

Timeframe: From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)

Population: Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The PD-L1-positive subpopulation (defined as patients in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization) who underwent primary tumor-reductive surgery.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=142 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=156 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population	13.44 Months Interval 12.71 to 19.29	17.71 Months Interval 15.01 to 19.61

SECONDARY outcome

Timeframe: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Population: Neoadjuvant Group. PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.

Clinically-meaningful improvement defined as a \>=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=157 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=152 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Presurgical/Surgery	54.2 Percentage of participants	50.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Cycle 4 Day 1	36.4 Percentage of participants	32.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Cycle 6 Day 1	55.0 Percentage of participants	48.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Cycle 16 Day 1	63.5 Percentage of participants	58.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Completion of Treatment/Early Termination Visit	51.0 Percentage of participants	51.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Post-Treatment Follow Up 3 Months	58.3 Percentage of participants	51.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Presurgical/Surgery	62.7 Percentage of participants	54.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Cycle 4 Day 1	65.0 Percentage of participants	59.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Cycle 16 Day 1	66.7 Percentage of participants	64.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Cycle 20 Day 1	66.3 Percentage of participants	56.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Completion of Treatment/ Early Termination Visit	62.1 Percentage of participants	58.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Post-Treatment Follow Up 3 Months	57.3 Percentage of participants	53.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Cycle 8 Day 1	64.3 Percentage of participants	54.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Cycle 12 Day 1	63.1 Percentage of participants	57.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Cycle 20 Day 1	68.7 Percentage of participants	48.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Post-Treatment Follow Up 6 Months	61.3 Percentage of participants	51.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Post-Treatment Follow Up 9 Months	60.5 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Post-Treatment Follow Up 12 Months	70.6 Percentage of participants	58.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Post-Treatment Follow Up 18 Months	100 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Abdominal Pain, Post-Treatment Follow Up 24 Months	100 Percentage of participants	100 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Cycle 6 Day 1	71.0 Percentage of participants	66.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Cycle 8 Day 1	71.9 Percentage of participants	63.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Cycle 12 Day 1	68.5 Percentage of participants	63.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Post-Treatment Follow Up 6 Months	59.2 Percentage of participants	62.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Post-Treatment Follow Up 9 Months	67.4 Percentage of participants	63.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Post-Treatment Follow Up 12 Months	47.1 Percentage of participants	62.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Post-Treatment Follow Up 18 Months	66.7 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group Bloating, Post-Treatment Follow Up 24 Months	0 Percentage of participants	100 Percentage of participants

SECONDARY outcome

Timeframe: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.

Clinically-meaningful improvement in patient-reported function and HRQoL during the treatment period, defined as a \>=10-point increase from the baseline score on each of the functional (social, emotional, physical, role) and GHS/QoLscales of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30).

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=157 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=152 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Post-Treatment Follow Up 12 Months	23.5 Percentage of participants	54.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Cycle 6 Day 1	35.6 Percentage of participants	25.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Cycle 8 Day 1	37.2 Percentage of participants	36.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Cycle 16 Day 1	42.7 Percentage of participants	42.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Completion of Treatment/Early Termination Visit	38.9 Percentage of participants	34.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Post-Treatment Follow Up 9 Months	32.6 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Post-Treatment Follow Up 12 Months	23.5 Percentage of participants	37.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Cycle 8 Day 1	50.4 Percentage of participants	39.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Post-Treatment Follow Up 18 Months	66.7 Percentage of participants	75.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Cycle 16 Day 1	44.8 Percentage of participants	42.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Post-Treatment Follow Up 9 months	39.5 Percentage of participants	34.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Post-Treatment Follow Up 12 months	29.4 Percentage of participants	29.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, PresurgicalSurgery	44.4 Percentage of participants	46.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Cycle 6 Day 1	51.1 Percentage of participants	47.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Post-Treatment Follow Up 24 Months	0 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Cycle 12 Day 1	45.9 Percentage of participants	43.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Cycle 20 Day 1	41.0 Percentage of participants	31.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Post-Treatment Follow Up 3 Months	37.1 Percentage of participants	39.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Presurgical/Surgery	35.9 Percentage of participants	33.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Cycle 4 Day 1	28.4 Percentage of participants	18.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Post-Treatment Follow Up 6 Months	40.8 Percentage of participants	39.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Post-Treatment Follow Up 18 Months	33.3 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Physical Functioning, Post-Treatment Follow Up 24 Months	100 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Presurgical/Surgery	48.6 Percentage of participants	40.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Cycle 4 Day 1	38.3 Percentage of participants	22.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Cycle 6 Day 1	45.9 Percentage of participants	33.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Cycle 12 Day 1	55.9 Percentage of participants	47.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Cycle 16 Day 1	53.1 Percentage of participants	46.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Cycle 20 Day 1	56.6 Percentage of participants	52.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Completion of Treatment/ Early Termination Visit	46.9 Percentage of participants	39.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Post-Treatment Follow Up 3 Months	49.5 Percentage of participants	40.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Post-Treatment Follow Up 6 Months	51.3 Percentage of participants	48.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Post-Treatment Follow Up 9 Months	53.5 Percentage of participants	52.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Post-Treatment Follow Up 18 Months	50.0 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Role Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Presurgical/Surgery	32.4 Percentage of participants	33.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Cycle 4 Day 1	31.2 Percentage of participants	25.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Cycle 6 Day 1	36.8 Percentage of participants	33.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Cycle 8 Day 1	40.3 Percentage of participants	39.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Cycle 12 Day 1	39.6 Percentage of participants	44.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Cycle 16 Day 1	40.0 Percentage of participants	44.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Cycle 20 Day 1	45.8 Percentage of participants	43.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Completion of Treatment/Early Termination	40.3 Percentage of participants	41.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Post-Treatment Follow Up 3 Months	42.7 Percentage of participants	44.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Post-Treatment Follow Up 6 Months	46.1 Percentage of participants	35.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Post-Treatment Follow Up 9 Months	46.5 Percentage of participants	47.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Social Functioning, Post-Treatment Follow Up 12 Months	29.4 Percentage of participants	54.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Presurgical/Surgery	31.7 Percentage of participants	30.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Cycle 4 Day 1	31.2 Percentage of participants	35.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Cycle 6 Day 1	42.1 Percentage of participants	38.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Cycle 8 Day 1	39.5 Percentage of participants	44.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Cycle 12 Day 1	41.4 Percentage of participants	41.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Cycle 20 Day 1	44.6 Percentage of participants	32.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Completion of Treatment/Early Termination Visit	33.8 Percentage of participants	33.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Post-Treatment Follow Up 3 months	35.4 Percentage of participants	33.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Post-Treatment Follow Up 6 months	30.3 Percentage of participants	33.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Post-Treatment Follow Up 18 months	16.7 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group Emotional Functioning, Post-Treatment Follow Up 24 months	0 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Cycle 4 Day 1	43.3 Percentage of participants	37.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Cycle 8 Day 1	55.0 Percentage of participants	59.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Cycle 12 Day 1	60.4 Percentage of participants	61.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Cycle 16 Day 1	53.1 Percentage of participants	58.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Cycle 20 Day 1	59.0 Percentage of participants	61.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Completion of Treatment/ Early Termination Visit	46.9 Percentage of participants	53.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Post-Treatment Follow Up 3 Months	53.7 Percentage of participants	53.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Post-Treatment Follow Up 6 Months	48.7 Percentage of participants	41.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Post-Treatment Follow Up 9 Months	39.5 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Post-Treatment Follow Up 12 Months	17.6 Percentage of participants	41.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group GHS/HRQoL, Post-Treatment Follow Up 18 Months	16.7 Percentage of participants	50.0 Percentage of participants

SECONDARY outcome

Timeframe: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.

Percentage of participants with clinical improvement, defined as \>= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=473 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=473 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 16 Day 1	32.1 Percentage of participants	34.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 5 Day 1	42.9 Percentage of participants	38.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 3 Months	42.7 Percentage of participants	41.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 20 Day 1	35.3 Percentage of participants	36.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 6 Months	39.2 Percentage of participants	34.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 9 Months	39.3 Percentage of participants	35.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 3 Day 1	22.6 Percentage of participants	19.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 5 Day 1	23.7 Percentage of participants	21.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 8 Day 1	28.7 Percentage of participants	27.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 12 Day 1	35.4 Percentage of participants	32.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 20 Day 1	34.8 Percentage of participants	32.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Completion of Treatment/Early Termination Visit	32.4 Percentage of participants	30.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 3 Months	35.7 Percentage of participants	28.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 6 Months	32.7 Percentage of participants	31.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 9 Months	34.5 Percentage of participants	27.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 12 Months	37.8 Percentage of participants	24.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 18 Months	42.9 Percentage of participants	18.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 3 Day 1	42.6 Percentage of participants	40.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 8 Day 1	47.5 Percentage of participants	45.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 12 Day 1	50.1 Percentage of participants	50.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 16 Day 1	52.0 Percentage of participants	50.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 20 Day 1	53.8 Percentage of participants	51.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Completion of Treatment/ Early Termination Visit	48.4 Percentage of participants	46.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 3 Months	54.0 Percentage of participants	45.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 6 Months	55.1 Percentage of participants	43.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 9 Months	57.1 Percentage of participants	38.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 12 Months	60 Percentage of participants	27.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 18 Months	50 Percentage of participants	43.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 24 Months	50 Percentage of participants	16.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 3 Day 1	30.1 Percentage of participants	31.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 5 Day 1	32.6 Percentage of participants	32.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 8 Day 1	37.8 Percentage of participants	38.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 12 Day 1	42.6 Percentage of participants	41.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 16 Day 1	43.5 Percentage of participants	48.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 20 Day 1	45.6 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Completion of Treatment/ Early Termination Visit	40.6 Percentage of participants	40.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 6 Months	43.2 Percentage of participants	34.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 9 Months	50.0 Percentage of participants	36.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 12 Months	62.2 Percentage of participants	36.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 18 Months	57.1 Percentage of participants	43.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 24 Months	100 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 3 Day 1	29.7 Percentage of participants	28.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 5 Day 1	30.3 Percentage of participants	30.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 8 Day 1	32.3 Percentage of participants	33.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 12 Day 1	34.6 Percentage of participants	36.1 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 16 Day 1	31.8 Percentage of participants	35.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Completion of Treatment/ Early Termination Visit	27.7 Percentage of participants	28.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 3 Months	29.1 Percentage of participants	27.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 6 Months	30.4 Percentage of participants	37.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 9 Months	38.1 Percentage of participants	33.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 12 Months	44.4 Percentage of participants	34.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 18 Months	42.9 Percentage of participants	31.3 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 24 Months	50.0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 3 Day 1	32.3 Percentage of participants	34.5 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 5 Day 1	33.0 Percentage of participants	31.0 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 8 Day 1	39.5 Percentage of participants	38.7 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 12 Day 1	41.5 Percentage of participants	43.4 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 16 Day 1	42.9 Percentage of participants	42.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 20 Day 1	42.5 Percentage of participants	46.2 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Completion of Treatment/ Early Termination Visit	38.0 Percentage of participants	34.9 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 3 Months	40.6 Percentage of participants	38.6 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 12 Months	40.0 Percentage of participants	32.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 18 Months	42.9 Percentage of participants	18.8 Percentage of participants
Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 24 Months	100 Percentage of participants	33.3 Percentage of participants

SECONDARY outcome

Timeframe: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.

Percentage of participants who remain stable defined as changes within 10 points from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=473 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=473 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 9 Months	46.4 Percentage of participants	46.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 12 Months	44.4 Percentage of participants	50.0 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 5 Day 1	30.1 Percentage of participants	33.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 8 Day 1	31.2 Percentage of participants	30.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 12 Day 1	32.9 Percentage of participants	32.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 20 Day 1	27.3 Percentage of participants	34.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 18 Months	42.9 Percentage of participants	25.0 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 5 Day 1	37.6 Percentage of participants	36.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 8 Day 1	40.2 Percentage of participants	35.2 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 12 Day 1	38.3 Percentage of participants	39.2 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 9 Months	53.6 Percentage of participants	48.0 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 12 Months	46.7 Percentage of participants	43.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 18 Months	50.0 Percentage of participants	37.5 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 12 Day 1	40.7 Percentage of participants	42.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 16 Day 1	38.4 Percentage of participants	43.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 20 Day 1	36.9 Percentage of participants	42.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Completion of Treatment/ Early Termination Visit	37.2 Percentage of participants	40.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 3 Months	38.9 Percentage of participants	38.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 6 Months	39.9 Percentage of participants	42.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 9 Months	39.3 Percentage of participants	38.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 12 Months	42.2 Percentage of participants	32.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 18 Months	35.7 Percentage of participants	37.5 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Post-Treatment Follow Up 24 Months	0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 3 Day 1	53.1 Percentage of participants	56.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 5 Day 1	49.0 Percentage of participants	50.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 8 Day 1	47.8 Percentage of participants	49.4 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 12 Day 1	47.1 Percentage of participants	51.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 16 Day 1	50.5 Percentage of participants	48.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 20 Day 1	46.6 Percentage of participants	50.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Completion of Treatment/ Early Termination Visit	46.8 Percentage of participants	44.5 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 3 Months	41.3 Percentage of participants	47.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 6 Months	42.2 Percentage of participants	43.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 18 Months	35.7 Percentage of participants	56.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 24 Months	100 Percentage of participants	33.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 3 Day 1	35.8 Percentage of participants	30.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 16 Day 1	27.6 Percentage of participants	33.4 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Completion of Treatment/ Early Termination Visit	28.6 Percentage of participants	28.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 3 Months	25.1 Percentage of participants	27.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 6 Months	24.5 Percentage of participants	29.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 9 Months	23.8 Percentage of participants	34.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 12 Months	33.3 Percentage of participants	34.5 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 24 Months	50 Percentage of participants	66.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 3 Day 1	40.7 Percentage of participants	36.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 16 Day 1	36.6 Percentage of participants	33.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 20 Day 1	34.1 Percentage of participants	33.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Completion of Treatment/ Early Termination Visit	31.9 Percentage of participants	31.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 3 Months	30.3 Percentage of participants	32.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 6 Months	33.8 Percentage of participants	34.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 9 Months	27.4 Percentage of participants	30.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 12 Months	28.9 Percentage of participants	25.9 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 18 Months	28.6 Percentage of participants	18.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 3 Day 1	57.5 Percentage of participants	57.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 5 Day 1	52.4 Percentage of participants	53.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 8 Day 1	53.2 Percentage of participants	54.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 12 Day 1	53.2 Percentage of participants	50.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 16 Day 1	55.0 Percentage of participants	51.3 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 20 Day 1	49.2 Percentage of participants	52.1 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Completion of Treatment/ Early Termination Visit	53.0 Percentage of participants	51.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 3 Months	51.3 Percentage of participants	55.5 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 6 Months	48.6 Percentage of participants	47.6 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 24 Months	50.0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 3 Day 1	43.3 Percentage of participants	42.2 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 5 Day 1	42.6 Percentage of participants	44.8 Percentage of participants
Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL, Cycle 8 Day 1	39.0 Percentage of participants	42.9 Percentage of participants

SECONDARY outcome

Timeframe: From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months). Cycle length=21 days.

Population: PRO-evaluable population is defined as patients in the ITT population with a baseline and \>=1 post-baseline PRO assessment.

Percentage of participants with deterioration in patient-reported function and HRQoL, defined as \>= 10 points decrease from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=473 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=473 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 6 Months	24.5 Percentage of participants	25.0 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 9 Months	19.0 Percentage of participants	25.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 12 Months	17.8 Percentage of participants	25.9 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 18 Months	21.4 Percentage of participants	25.0 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	50 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 3 Day 1	21.3 Percentage of participants	27.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 5 Day 1	26.7 Percentage of participants	27.0 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 8 Day 1	21.1 Percentage of participants	22.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 12 Day 1	16.7 Percentage of participants	16.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 3 Day 1	24.1 Percentage of participants	24.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 5 Day 1	27.1 Percentage of participants	28.6 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 8 Day 1	23.4 Percentage of participants	23.6 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 12 Day 1	17.2 Percentage of participants	16.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 16 Day 1	17.1 Percentage of participants	17.0 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Cycle 20 Day 1	18.2 Percentage of participants	16.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Completion of Treatment/ Early Termination Visit	20.5 Percentage of participants	25.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Physical Functioning, Post-Treatment Follow Up 3 Months	22.6 Percentage of participants	23.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 16 Day 1	20.1 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Completion of Treatment/ Early Termination Visit	23.0 Percentage of participants	24.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 3 Months	20.9 Percentage of participants	27.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 6 Months	20.4 Percentage of participants	25.6 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 9 Months	19.0 Percentage of participants	26.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 12 Months	6.7 Percentage of participants	37.9 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 18 Months	7.1 Percentage of participants	31.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 3 Day 1	29.0 Percentage of participants	31.2 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 5 Day 1	29.6 Percentage of participants	30.6 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 8 Day 1	21.8 Percentage of participants	25.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 12 Day 1	18.9 Percentage of participants	19.0 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 16 Day 1	19.5 Percentage of participants	17.6 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Cycle 20 Day 1	20.2 Percentage of participants	16.2 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Completion of Treatment/ Early Termination Visit	27.2 Percentage of participants	28.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 3 Months	26.5 Percentage of participants	25.4 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 6 Months	23.0 Percentage of participants	30.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 9 Months	22.6 Percentage of participants	32.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 12 Months	8.9 Percentage of participants	37.9 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 18 Months	14.3 Percentage of participants	37.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Social Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	33.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 3 Day 1	12.8 Percentage of participants	14.0 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 5 Day 1	17.3 Percentage of participants	15.9 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 8 Day 1	14.6 Percentage of participants	12.4 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 16 Day 1	13.2 Percentage of participants	12.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 20 Day 1	15.5 Percentage of participants	11.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Completion of Treatment/ Early Termination Visit	19.3 Percentage of participants	19.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 9 Months	8.3 Percentage of participants	18.4 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Cycle 3 Day 1	24.2 Percentage of participants	22.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Cycle 8 Day 1	21.3 Percentage of participants	18.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Post-Treatment Follow Up 3 Months	20.5 Percentage of participants	22.9 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Post-Treatment Follow Up 18 Months	21.4 Percentage of participants	43.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Role Functioning, Cycle 20 Day 1	18.6 Percentage of participants	13.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Cycle 12 Day 1	12.2 Percentage of participants	13.4 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 3 Months	19.7 Percentage of participants	16.9 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 6 Months	20.9 Percentage of participants	14.6 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 12 Months	8.9 Percentage of participants	22.4 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 18 Months	7.1 Percentage of participants	31.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group Emotional Functioning, Post-Treatment Follow Up 24 Months	0 Percentage of participants	66.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Cycle 5 Day 1	24.1 Percentage of participants	23.7 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Cycle 12 Day 1	17.6 Percentage of participants	13.2 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Cycle 16 Day 1	18.3 Percentage of participants	13.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Cycle 20 Day 1	20.2 Percentage of participants	11.1 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Completion of Treatment/ Early Termination Visit	24.5 Percentage of participants	24.3 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Post-Treatment Follow Up 6 Months	20.9 Percentage of participants	23.8 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Post-Treatment Follow Up 9 Months	21.4 Percentage of participants	25.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Post-Treatment Follow Up 12 Months	17.8 Percentage of participants	34.5 Percentage of participants
Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group GHS/OoL Function, Post-Treatment Follow Up 24 Months	0 Percentage of participants	50.0 Percentage of participants

SECONDARY outcome

Timeframe: From randomization up to approximately 59 months

Population: Safety-evaluable population is defined as patients who received any amount of any study treatment (atezolizumab, placebo, paclitaxel, carboplatin, or bevacizumab).

Percentage of participants with at least one adverse event.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=644 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=642 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants With at Least One Adverse Event	99.8 Percentage	100 Percentage

SECONDARY outcome

Timeframe: Cycle 1 Day 1 post dose and Cycle 3 Day 1 post dose

Population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=538 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Maximum Serum Concentration (Cmax) of Atezolizumab Cycle 1 Day 1	487 µg/mL Standard Deviation 163	—
Maximum Serum Concentration (Cmax) of Atezolizumab Cycle 3 Day 1	614 µg/mL Standard Deviation 209	—

SECONDARY outcome

Timeframe: Cycle 2 Day 1 predose, Cycle 3 Day 1 Predose, Cycle 4 Day 1 predose, Cycle 8 Day 1 predose, Cycle 16 Day 1 predose

Population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=532 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Minimum Serum Concentration (Cmin) of Atezolizumab Cycle 2 Day 1	88.9 µg/mL Standard Deviation 35.8	—
Minimum Serum Concentration (Cmin) of Atezolizumab Cycle 3 Day 1	146 µg/mL Standard Deviation 93.0	—
Minimum Serum Concentration (Cmin) of Atezolizumab Cycle 4 Day 1	149 µg/mL Standard Deviation 88.1	—
Minimum Serum Concentration (Cmin) of Atezolizumab Cycle 8 Day 1	242 µg/mL Standard Deviation 96.3	—
Minimum Serum Concentration (Cmin) of Atezolizumab Cycle 16 Day 1	286 µg/mL Standard Deviation 111	—

SECONDARY outcome

Timeframe: Baseline to approximately 55 months

Population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.

Outcome measures

Outcome measures
Measure	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=569 Participants Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab Baseline evaluable participants	0.7 Percentage of participants	—
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab Post-baseline evaluable participants	22.7 Percentage of participants	—

Adverse Events

Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab

Serious events: 304 serious events

Other events: 637 other events

Deaths: 272 deaths

Placebo With Paclitaxel, Carboplatin and Bevacizumab

Serious events: 215 serious events

Other events: 637 other events

Deaths: 289 deaths

Serious adverse events

Other adverse events

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800-821-8590

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER

Serious adverse events
Measure	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=642 participants at risk Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=644 participants at risk Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.
Injury, poisoning and procedural complications FALL	0.31% 2/642 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Injury, poisoning and procedural complications FASCIAL RUPTURE	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders AGRANULOCYTOSIS	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.31% 2/644 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders ANAEMIA	0.93% 6/642 • Number of events 7 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	1.6% 10/644 • Number of events 10 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders FEBRILE NEUTROPENIA	8.4% 54/642 • Number of events 59 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	3.7% 24/644 • Number of events 25 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders GRANULOCYTOSIS	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders IMMUNE THROMBOCYTOPENIA	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders LEUKOPENIA	0.47% 3/642 • Number of events 3 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.31% 2/644 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders NEUTROPENIA	0.78% 5/642 • Number of events 5 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.78% 5/644 • Number of events 5 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders PANCYTOPENIA	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.31% 2/644 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders THROMBOCYTOPENIA	1.2% 8/642 • Number of events 11 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	1.6% 10/644 • Number of events 12 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders THROMBOTIC MICROANGIOPATHY	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	0.31% 2/642 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ANGINA UNSTABLE	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ARRHYTHMIA	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ATRIAL FIBRILLATION	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ATRIAL TACHYCARDIA	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ATRIAL THROMBOSIS	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders ATRIOVENTRICULAR BLOCK	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders CARDIAC ARREST	0.31% 2/642 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders CARDIAC FAILURE	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders CARDIAC FAILURE CONGESTIVE	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders CARDIOMYOPATHY	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders CARDIOVASCULAR DISORDER	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders MYOCARDIAL INFARCTION	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders MYOCARDIAL ISCHAEMIA	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders MYOCARDITIS	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Cardiac disorders PALPITATIONS	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Ear and labyrinth disorders OTOLITHIASIS	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Ear and labyrinth disorders VERTIGO	0.00% 0/642 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.47% 3/644 • Number of events 3 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders ADDISON'S DISEASE	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders ADRENAL INSUFFICIENCY	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders AUTOIMMUNE THYROIDITIS	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders HYPERPARATHYROIDISM	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders HYPOTHYROIDISM	0.31% 2/642 • Number of events 2 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.16% 1/644 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders SECONDARY ADRENOCORTICAL INSUFFICIENCY	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Eye disorders OCULAR MYASTHENIA	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Eye disorders OPTIC NEUROPATHY	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Eye disorders RETINAL VEIN OCCLUSION	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Eye disorders ULCERATIVE KERATITIS	0.16% 1/642 • Number of events 1 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	0.00% 0/644 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.

Other adverse events
Measure	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab n=642 participants at risk Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Placebo With Paclitaxel, Carboplatin and Bevacizumab n=644 participants at risk Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.
Blood and lymphatic system disorders ANAEMIA	44.2% 284/642 • Number of events 468 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	41.3% 266/644 • Number of events 440 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders LEUKOPENIA	10.7% 69/642 • Number of events 197 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	11.8% 76/644 • Number of events 243 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders NEUTROPENIA	30.4% 195/642 • Number of events 477 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	30.6% 197/644 • Number of events 507 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Blood and lymphatic system disorders THROMBOCYTOPENIA	21.3% 137/642 • Number of events 278 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	20.8% 134/644 • Number of events 275 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders HYPERTHYROIDISM	7.9% 51/642 • Number of events 56 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	3.6% 23/644 • Number of events 26 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Endocrine disorders HYPOTHYROIDISM	18.4% 118/642 • Number of events 131 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	8.4% 54/644 • Number of events 57 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Eye disorders VISION BLURRED	4.8% 31/642 • Number of events 34 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	7.0% 45/644 • Number of events 48 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders ABDOMINAL DISTENSION	6.1% 39/642 • Number of events 51 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	7.6% 49/644 • Number of events 60 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders ABDOMINAL PAIN	28.3% 182/642 • Number of events 253 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	26.9% 173/644 • Number of events 241 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders ABDOMINAL PAIN UPPER	7.6% 49/642 • Number of events 56 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	10.2% 66/644 • Number of events 98 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders CONSTIPATION	35.2% 226/642 • Number of events 297 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	37.3% 240/644 • Number of events 334 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders DIARRHOEA	34.7% 223/642 • Number of events 336 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	30.9% 199/644 • Number of events 328 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders DRY MOUTH	5.3% 34/642 • Number of events 39 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	2.8% 18/644 • Number of events 22 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders DYSPEPSIA	6.9% 44/642 • Number of events 54 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	8.2% 53/644 • Number of events 61 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders NAUSEA	50.6% 325/642 • Number of events 565 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	52.3% 337/644 • Number of events 628 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders STOMATITIS	15.3% 98/642 • Number of events 138 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	10.4% 67/644 • Number of events 106 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Gastrointestinal disorders VOMITING	23.4% 150/642 • Number of events 209 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	24.2% 156/644 • Number of events 230 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
General disorders ASTHENIA	12.1% 78/642 • Number of events 102 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	12.3% 79/644 • Number of events 117 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
General disorders FATIGUE	37.5% 241/642 • Number of events 297 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	39.0% 251/644 • Number of events 339 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
General disorders MALAISE	5.5% 35/642 • Number of events 59 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	5.1% 33/644 • Number of events 42 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
General disorders MUCOSAL INFLAMMATION	7.0% 45/642 • Number of events 49 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	4.0% 26/644 • Number of events 36 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
General disorders OEDEMA PERIPHERAL	6.2% 40/642 • Number of events 44 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	6.2% 40/644 • Number of events 42 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
General disorders PYREXIA	16.2% 104/642 • Number of events 124 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	8.4% 54/644 • Number of events 75 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Infections and infestations NASOPHARYNGITIS	6.4% 41/642 • Number of events 60 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	6.4% 41/644 • Number of events 59 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	9.8% 63/642 • Number of events 83 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	8.5% 55/644 • Number of events 71 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Infections and infestations URINARY TRACT INFECTION	17.0% 109/642 • Number of events 169 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	16.1% 104/644 • Number of events 140 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Injury, poisoning and procedural complications INFUSION RELATED REACTION	12.1% 78/642 • Number of events 116 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	7.8% 50/644 • Number of events 71 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations ALANINE AMINOTRANSFERASE INCREASED	14.2% 91/642 • Number of events 142 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	9.2% 59/644 • Number of events 100 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations ASPARTATE AMINOTRANSFERASE INCREASED	13.9% 89/642 • Number of events 149 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	8.7% 56/644 • Number of events 93 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED	6.2% 40/642 • Number of events 50 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	5.1% 33/644 • Number of events 48 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations LYMPHOCYTE COUNT DECREASED	6.5% 42/642 • Number of events 55 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	3.7% 24/644 • Number of events 44 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations NEUTROPHIL COUNT DECREASED	27.6% 177/642 • Number of events 567 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	26.1% 168/644 • Number of events 610 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations PLATELET COUNT DECREASED	21.3% 137/642 • Number of events 267 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	22.0% 142/644 • Number of events 329 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations WEIGHT DECREASED	13.1% 84/642 • Number of events 91 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	10.6% 68/644 • Number of events 72 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations WEIGHT INCREASED	7.8% 50/642 • Number of events 51 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	6.8% 44/644 • Number of events 46 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Investigations WHITE BLOOD CELL COUNT DECREASED	22.3% 143/642 • Number of events 455 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	18.9% 122/644 • Number of events 535 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Metabolism and nutrition disorders DECREASED APPETITE	18.5% 119/642 • Number of events 160 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	18.6% 120/644 • Number of events 154 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Metabolism and nutrition disorders HYPERGLYCAEMIA	7.2% 46/642 • Number of events 69 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	8.1% 52/644 • Number of events 85 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Metabolism and nutrition disorders HYPOKALAEMIA	11.2% 72/642 • Number of events 97 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	9.3% 60/644 • Number of events 94 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.
Metabolism and nutrition disorders HYPOMAGNESAEMIA	14.3% 92/642 • Number of events 134 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.	12.9% 83/644 • Number of events 112 • From the first study drug to the data cutoff date: 12 August 2022 (up to 65 months) All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \& other adverse events reported based on safety population, which included participants who received any amount of any study drug.